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Abstract: Immunotherapy by sublingual administration of allergens provides high patient 
compliance and has emerged as an alternative to subcutaneous immunotherapy for the  treatment 
of IgE-associated allergic diseases. However, sublingual immunotherapy (SLIT) can cause 
adverse events. Development of allergen delivery systems enabling more efficient delivery 
and hence lower allergen load might reduce the adverse events. In the present study, we have 
investigated neutral and cationic liposomes as delivery systems of ovalbumin (OVA), as a model 
allergen, in an OVA-induced allergic airway inflammation model. We investigated the liposome 
carriers’ ability to improve tolerance induction of antigens compared to the  corresponding dose 
of free OVA. Mice were treated sublingually over 2 weeks with free or liposome encapsu-
lated OVA followed by intraperitoneal injections and intranasal challenge. Mice sublingually 
treated with OVA-liposomes showed a significant reduction of airway eosinophilia and sple-
nocyte proliferation in comparison to free OVA. A similar nonsignificant pattern was seen for 
OVA-specific IgE antibodies. In addition, reduced levels of interferon-γ and interleukin-5 were 
observed in spleen cell culture supernatants from OVA-liposome-treated mice compared to the 
sham-treated group. In conclusion, in vivo efficacy data showed that prophylactic SLIT with 
OVA-liposomes is significantly more effective in preventing allergic inflammation than the 
corresponding dose of free OVA.
Keywords: sublingual immunotherapy, drug delivery, allergy, liposome
Introduction
The prevalence of IgE-mediated allergic diseases has increased more than two-fold 
during the last decades, and currently .30% of the population in industrialized coun-
tries are allergic to aeroallergens such as pollens and house dust mites.1,2 Allergen-
specific immunotherapy (AIT) is an effective therapy for IgE-mediated respiratory 
allergic diseases and has a potentially sustained effect after completed treatment.3,4 
Sublingual immunotherapy (SLIT), formulated as fluids or as fast dissolving allergen 
immunotherapy tablets, demonstrates safety and clinical efficacy and has recently 
emerged as an alternative to subcutaneous immunotherapy (SCIT) with improve-
ments on adverse events.3,5–7 The immunological mechanisms of SLIT are not entirely 
understood; however, it is believed that sublingually administered allergens are taken 
up by antigen presenting cells (APCs), mainly dendritic cells (DCs), and thereafter 
processed while the APCs migrate to regional lymph nodes to present the antigen.8,9 
SLIT has been shown to induce a shift from the allergy promoting Th2 cells (interleukin 
[IL]-4, IL-5, and IL-13) toward Th1 cells (interferon [IFN]-γ), induce allergen-specific 
regulatory T-cells, and produce allergen-specific IgA and IgG, mainly IgG4.10–13 The 
treatment duration for SLIT is 3–5 years and even though SLIT is considered to 
have a better safety profile than SCIT,14 it can cause local adverse events and clinical 
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supervision is required for the first administration.12,13 SLIT 
relies on high allergen extract doses compared to SCIT11 and 
adverse events can potentially be reduced if the administra-
tion dose is decreased which in turn will lead to an improved 
safety profile.
Encapsulation of allergens in liposomes that can act as 
allergen delivery systems,15 offers the ability to protect the 
allergen from degradation, potentially aid transport within 
tissues, and in turn target APCs.16 Thus, the use of liposomes 
as a delivery system could decrease the allergen dose required 
for successful SLIT and improve the safety profile. Lipo-
somes are able to entrap proteins in the aqueous interior and 
have been widely used as drug delivery carriers due to their 
high biocompatibility.17 Different parameters such as size, 
surface charge, composition, and mechanical stability can be 
controlled by lipid composition,18 which may affect trans-
port through sublingual mucosa and immune cell targeting. 
Nanocarrier based drugs (including liposomes) are under 
investigation for treatment of a range of diseases,19–21 and a 
number of technologies have reached late stage clinical devel-
opment, while others have reached the market.22 It is the gold 
standard in nanocarrier technology for in vivo use to surface 
coat the nanoparticles with polyethylene glycol (PEG), which 
masks the nanocarrier from the mononuclear phagocytic 
system and thereby increases nanocarrier half-life in blood 
after intravenous administration. Interestingly, it has also 
been shown that PEG can change the adhesion properties 
between nanoparticles and mucin fibers in mucosal tissues, 
and as a result may enhance their penetration through layers 
of sublingual mucosa.23,24 As of today, none of the com-
mercially available SLIT vaccines contain any adjuvants.25 
However, a few studies have shown positive results in 
murine SLIT models using positively charged maltodextrin 
and chitosan based microparticles as antigen carriers for 
mucosal vaccination, where the immune response was 
enhanced through DC targeting.26,27 One study showed that 
sublingual administration of ovalbumin (OVA) formulated 
with mucoadhesive maltodextrin matrix was very effective in 
reducing the airway eosinophil accumulation and decreasing 
Th2 allergic responses in an OVA-induced allergic airway 
inflammation model.26 Another SLIT study showed that 
cationic chitosan based nanoparticles carrying OVA could 
target DC and offer a tendency in lowering Th2 responses 
when administered sublingually after sensitization in an 
asthma model.27 To our knowledge, liposomes have not yet 
been investigated for SLIT applications.
In this paper, we have investigated the possibility of 
developing liposomes as a new allergen delivery system 
for improving efficacy of SLIT in an OVA-induced allergic 
airway inflammation model. OVA was encapsulated in 
liposomes with varying amounts of cationic lipids and was 
investigated for the ability to improve allergen-specific toler-
ance compared to free OVA.
Materials and methods
chemicals
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2- 
dioleoyl-3-trimethylammonium-propane (DOTAP), 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(methoxy[PEG]-1000) (ammonium salt) (DOPE-PEG1000), 
and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(methoxy[PEG]-2000) (ammonium salt) (DOPE-PEG2000) 
were purchased from Avanti Polar Lipids (Alabaster, AL, 
USA). OVA grade V from chicken egg white (OVA) was 
purchased from Sigma Aldrich (St Louis, MO, USA) and 
phosphate-buffered saline (PBS) buffer was obtained from 
Lonza (Capsugel Bornem, Belgium).
liposome preparation
Stock solutions of 100 mM of each lipid used were prepared in 
chloroform:methanol (9:1) in 8 mL flat bottom glass vials, and 
then mixed into a homogeneous mixture at the desired molar 
ratios. The organic solvent was evaporated in a fume head 
using dry nitrogen steam for 3 hours. Further, the lipid film was 
thoroughly dried using a vacuum system to form a thin layer 
lipid film on the bottom of the vial. The lipid film was hydrated 
at room temperature in PBS containing the desired amount 
of OVA (100 mg/mL for the in vivo studies). The vials were 
stirred for 10 seconds every fifth minute during 1 hour and, as 
a result, 100 mM multilamellar liposomes encapsulating OVA 
were formed. Liposomes were extruded 21 times through a 
nuclepore polycarbonate membrane with a pore size of 100 
nm from Whatman (Maidstone, UK), using the Avanti-syringe 
extruder. Liposomes were formulated with a total lipid con-
centration of 100 mM as mixtures of POPC:DOTAP:DOPE-
PEG1000 lipids and DOPC:DOTAP:DOPE-PEG1000 lipids. 
Different molar ratios with the above mixtures were formu-
lated: 98:1:1 (OVA-POPC neutral) and 93:6:1 (OVA-POPC 
cationic), as well as 98:1:1 (OVA-DOPC neutral) and 93:6:1 
(OVA-DOPC cationic). Empty liposomes without OVA were 
formulated as negative control with the same lipid composition 
as the OVA-liposomes. Size exclusion chromatography (SEC), 
using a 20 cm column packed with Sepharose CL-4b from 
GE Healthcare Europe GmbH (Freiburg, Germany), was used 
to separate liposome encapsulated OVA (OVA-liposomes) 
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from free OVA. Thereafter, the liposomes were centrifuged in 
Amicon ultra-15 centrifugal filter units 100,000 MWCO from 
Merck Millipore (Billerica, MA, USA) to the initial volume 
prior to SEC (1 mL), to ensure sufficiently high concentration 
for in vivo use. 
size measurement of liposomes
The liposome samples were diluted to a final lipid concen-
tration of 0.1 mM for measurement in PBS and the size and 
polydispersity index (PDI) of the liposomes were measured as 
replicates 5× for 30 seconds each using a ZetaPALS dynamic 
light scattering (DLS) system from Brookhaven Instruments 
Corporation (Holtsville, NY, USA).
lipid and encapsulated OVa 
quantification of the liposomes
Amino acid analysis (AAA) was used for quantifying soluble 
or encapsulated OVA prior to SLIT. In short, samples were 
hydrolyzed for 24 hours in 6 M HCl where amino acids were 
separated by ion exchange chromatography. After oxidation 
and derivatization with ortho-phthalaldehyde, the amino acids 
were detected using a fluorescence detector (Waters M 474; 
Waters Corporation, Milford, MA, USA) with 338 nm 
bandpass excitation filter and 450 nm long-pass emission 
filter. A standard mixture containing 1 nmol of the amino 
acids was used to identify and quantify each amino acid.28 
Lipid concentration was determined by measuring the total 
phosphorous content with inductively coupled plasma mass 
spectrometry (ICP-MS) using a Dionex ICS-5000+ system 
(Thermo Fisher Scientific, Waltham, MA, USA). Samples 
were analyzed by diluting 5,000-fold in 2% HCl containing 
10 ppb of gallium as an internal standard. 
OVA leakage from liposomes
OVA-POPC cationic and OVA-DOPC cationic liposomes 
were preserved at 4°C in aliquots of 200 µL, in order to 
study OVA leakage from the liposomes over time. Leakage 
was assessed by centrifugation of the liposome samples at 
1,000× g in Amicon ultra-0.5 centrifugal filter unit with 
Ultracel-100 membrane 100,000 MWCO filter units from 
Merck Millipore at 5°C for 3 hours. The leakage of OVA was 
determined by analyzing the filtrate with AAA and comparing 
to the OVA concentration in the batch.
animals 
Six-week old Balb/cJ female mice were purchased from 
Taconic, Ejby, Denmark and maintained on an OVA-free 
diet. The mice were housed in a pathogen-free environment 
with 12 hour light, 12 hour dark cycles. All experiments 
described in this report were conducted in accordance with 
Danish legislation as stipulated in the Animal Experimenta-
tion Act issued by the Ministry of Environment and Food 
of Denmark. Ethical and legal permissions were obtained 
prior to the start of the study by the Supervisory Authority 
on Animal Testing in Glostrup, Denmark.
In vivo experimental design
Mice were treated sublingually 5 times/week with either 
50 µg of OVA-liposomes, a corresponding dose of free 
OVA (50 µg), a 10-fold higher dose of free OVA (positive 
control for treatment effect), or PBS buffer during a 2-week 
period (Monday–Friday). SLIT was performed by holding 
mice in the scruff and applying 10 µL of the respective 
treatment under the tongue. Mice were fixed for additional 
20 seconds to prevent immediate swallowing of the solution. 
Thereafter, they were sensitized by two intraperitoneal (i.p) 
injections of 25 µg alum-adsorbed OVA in 250 µL buffer 
solution at day 15 and 29, followed by three intranasal 
challenges with 10 µg OVA in 25 µL buffer solution at day 
36–38, and were sacrificed at day 39 (Figure 1). Eosinophils 
in bronchoalveolar lavage (BAL), allergen-specific IgE in 
serum, in vitro proliferation, and Th2 cytokine responses 
 'D\    ± 
6/,7WLPHVZHHN
îLSVHQVLWL]DWLRQ îLQFKDOOHQJH
6DPSOLQJEORRGVSOHHQ%$/
Figure 1 Schematic image of prophylactic experimental design. 
Notes: Mice were treated sublingually 5 times/week with 10 µL of OVA-liposomes (50 µg OVA), free OVA (50 or 500 µg), or PBS buffer. All mice were subsequently 
sensitized by two i.p injections with 25 µg alum-adsorbed OVA in 250 µL buffer solution followed by i.n challenge with 10 µg of OVA in 25 µL buffer solution over 3 
consecutive days. Mice were sacrificed the following day. Blood and spleen were collected and BAL was performed.
Abbreviations: OVA, ovalbumin; PBS, phosphate-buffered saline; i.p, intraperitoneal; BAL, bronchoalveolar lavage; i.n, intranasal; SLIT, sublingual immunotherapy.
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from spleen cells were used as readouts for SLIT efficacy. 
Control animals were sham-SLIT-treated with PBS buffer 
as negative control and OVA 500 µg/SLIT dose as positive 
treatment control. Each experimental group was composed 
of eight mice.
eosinophils measurements in Bal 
BAL was performed by using 750 µL of Hank’s balanced 
salt solution (Thermo Fisher Scientific) complemented with 
protease inhibitor cocktail tablet (Roche, Basel, Switzerland). 
The BAL fluid was centrifuged for 7 minutes at 400× g at 
8°C and the pellet, containing the cells, was resuspended in 
100 µL PBS. Cells were differentially counted by a Sysmex 
XT1800i hematology analyzer (Sysmex, Kobe, Japan).
OVA IgE quantification of serum
Serum was prepared by centrifuging blood in BD Microtainer 
serum separator tubes (BD, Tense, Belgium) for 7 minutes, 
400× g at room temperature. OVA IgE was measured 
using mouse OVA IgE enzyme-linked immunosorbent 
assay (ELISA) kit (MD Bioproducts, Zurich, Switzerland). 
In short, standards and analytical samples were diluted and 
added to the wells. OVA IgE was detected by adding the 
biotin conjugate and streptavidin-horseradish peroxidase. 
The plates were developed with substrate and stopped after 
15 minutes. Absorbance was measured with an ELISA reader 
(ultra microplate reader, EL808; BioTek Instruments, Inc, 
Winooski, VT, USA) at 450 nm.
Cell proliferation and cytokine 
production 
The spleen was processed to a single cell suspension by 
squeezing through a falcon nylon filter (VWR International, 
Denmark) and washed three times in RPMI-1640 (Lonza) 
supplemented with 0.05 mg/mL gentamycin (Thermo Fisher 
Scientific). Cells were dispersed and counted to a concentra-
tion of 3.0×106 cells/mL in RPMI-1640 medium containing 
1% Nutridoma (Roche), 1.5 mM monothioglycerol (Sigma), 
0.05 mg/mL gentamycin, and 2.5% fetal calf serum (Thermo 
Fisher Scientific). In total, 5.4×105 and 2.4×105 cells were 
plated on a flat bottomed 96-well Nunc plate for assess-
ment of proliferation and cytokine production. Cells were 
stimulated with a final concentration of 5, 25, or 125 µg/mL 
of OVA and the proliferation plates were incubated for 
6 days at 37°C and 5.5% CO
2
. The cells were treated with 
3H-thymidine for the last 17 hours and splenocyte prolifera-
tion was measured by counting the incorporated radiolabel 
on a Wallac Microbeta 1450 liquid scintillation counter 
(Wallac, Wellesley, USA) after harvesting the cells on a 
Tomtec-96-well plate harvester (Tomtec Inc, Hamden, CT, 
USA). For measurement of cytokine levels, the cell concen-
tration in the wells was adjusted to 5.4×105 and supernatants 
were collected after 5 days of culture.
Cytokine measurement by ELISA-based 
method
The cytokine levels were measured on a custom made 
MULTI-SPOT®, 7 Spot Mouse 6plex from Meso Scale 
Discovery (Rockville, MD, USA), where IFN-γ, IL-4, IL-5, 
IL-10, IL-13, and IL-17 analytes were measured according to 
their manual. In short, samples and calibrators are added to 
cytokine pre-coated wells followed by addition of detection 
antibody. Read buffer was added and the plates were analyzed 
in the MSD reader (MESO Sector S600) within 15 minutes.
Data analysis
Statistical analyses were performed with GraphPad Prism 
software program (version 6.1; GraphPad Software Inc, 
La Jolla, CA, USA) using one-way analysis of variance or 
Kruskal–Wallis test and P-values were adjusted for multiple 
comparisons by Holm–Sidak’s and Dunn’s test, respectively. 
P-values ,0.05 are considered significant, where * indicates 
P,0.05, ** indicates P,0.01, *** indicates P,0.005, and 
**** indicates P,0.001. Data are expressed as mean value 
of the group + standard error of means.
Results
Optimization of liposomes 
SLIT treatment in mice generally requires a high concentra-
tion of OVA to induce tolerance. It was therefore of interest 
to encapsulate OVA in the liposome formulations in order 
to lower the SLIT dose. Different factors affecting the 
encapsulation capacity were investigated. A main factor that 
proved to be essential in the liposomal formulation was the 
incorporation of PEG on the liposome surface, as the extru-
sion of OVA-liposomes in the absence of PEG proved to be 
very challenging when using a high concentration of OVA. 
Liposomes were formulated with either POPC or DOPC as 
the main lipid components. Different amounts of the cationic 
lipid DOTAP (net charge of +1), were added to the liposome 
formulations for obtaining liposomes with variable cationic 
surface charge. OVA was encapsulated by hydrating a lipid 
film in the presence of OVA. OVA is negatively charged at 
isotonic pH with an isoelectric point of 4.8, and is believed 
to provoke aggregation complexes with positively charged 
liposomes by electrostatic interaction.29 To circumvent 
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aggregation, two different sizes of PEG polymers attached to 
DOPE lipids, DOPE-PEG1000 and DOPE-PEG2000, were 
used in different concentrations (Table 1).
Size measurements of OVA-liposomes showed no 
difference between DOPE-PEG1000 and DOPE-PEG2000. 
However, increasing the PEG-lipid concentrations resulted 
in larger OVA-liposomes with high PDI. In addition to the 
above-mentioned parameters, both ultrasonication (probe 
and bath) and extrusion were tested for the ability of these 
methods to obtain homogeneous liposomes in high OVA 
and lipid concentration. The experimental results showed that 
extrusion gave more homogeneous liposome populations and 
smaller average size than ultrasonication (~150 nm for extru-
sion and ~300 nm for sonication [frequency 50 kHz] at high 
concentration of OVA and lipid). In addition, 10 mM acetate 
buffer, 10 mM 2-(N-Morpholino)ethanesulfonic acid sodium 
salt (MES) buffer, 10 mM phosphate buffer including 37.5 mM 
NaCl with pH ranging between 4.0 and 7.4 were tested, which 
did not improve the liposome preparations in terms of easier 
extrusion (data not shown). After evaluating the formulation 
procedure, OVA as well as liposomal concentration were 
increased to 100 mg/mL and 100 mM, respectively, giving the 
highest degree of encapsulated OVA in the liposomes.
OVa entrapment and lipid concentration 
of liposomes 
Upon optimization of the liposome preparation procedure, 
four different OVA-liposome systems were chosen for 
further studies where size stability was evaluated. The four 
liposome systems had various degrees of cationic lipid and 
were based on either POPC or DOPC, and DOPE-PEG1000 
as described in Table 2.
SEC was used to separate liposome encapsulated OVA from 
free OVA after hydrating lipid films in the presence of OVA 
and after extrusion. The liposomes were further concentrated 
using centrifuge filters, after which the OVA encapsulation was 
evaluated for the different formulations. The remaining OVA 
concentration varied between 6.5 and 7.5 mg/mL, giving an 
encapsulation efficiency of around 10% (Table 2). Total lipid 
concentration of the different liposome formulations was quanti-
fied to be between 70 and 85 mM, by measuring the phosphorus 
in the samples using ICP-MS. The liposomes were used imme-
diately after protein quantification in the in vivo studies.
Characterization and physical stability of 
liposomes 
Size distributions were measured using DLS, which showed 
that the mean particle diameters were between 140 and 
155 nm with PDI of around 0.1 for both OVA-POPC and 
OVA-DOPC liposomes. The diameter of “empty” POPC 
or DOPC liposomes with cationic charge (containing only 
PBS) was used as a comparison and was in the same size 
range (Figure 2).
Physical stability tests of samples preserved at 4°C over a 
period of 4.5 months showed that the sizes of the liposomes 
were stable during the stability testing period (Figure 2) 
and did not aggregate. Overall, the results demonstrate that 
the particles are homogeneous and stable for a period of at 
least 4.5 months. Additional studies of OVA-POPC cationic 
liposomes showed physical stability for at least 7 months 
when evaluated monthly by measuring the diameter and PDI 
(data not shown).
OVA encapsulation stability in liposomes
To study the leakage over time of OVA from the liposomes, 
OVA-POPC and OVA-DOPC cationic liposomes pre-
served at 4°C were centrifuged through centrifuge filters at 
5°C allowing the OVA to pass and retaining the liposome 
Table 1 Different parameters tested for optimizing liposome 
formulations to obtain the highest possible encapsulated OVA 
concentration for slIT treatment
Lipid 
composition 
(molar ratio)
Theoretical 
lipid conc 
(mM)
Theoretical 
OVA conc 
(mg/mL)
Lipid to 
protein 
ratio
Size 
(nm)*
PDI*
POPC:DOTAP:DOPE-PEG2000
93:6:1 13 5 2.6 170 0.11
88:11:1 13 5 2.6 315 0.3
83:16:1 13 5 2.6 601 0.35
90:7.5:2.5 13 5 2.6 160 0.12
85:12.5:2.5 13 5 2.6 310 0.29
80:17.5:2.5 13 5 2.6 440 0.3
93:6:1 26 5 5.2 143 0.16
90:7.5:2.5 26 5 5.2 156 0.15
POPC:DOTAP:DOPE-PEG1000
93:6:1 13 5 2.6 170 0.1
90:7.5:2.5 13 5 2.6 175 0.14
93:6:1 26 5 5.2 153 0.13
90:7.5:2.5 26 5 5.2 186 0.22
93:6:1 50 20 2.5 190 0.9
93:6:1 75 30 2.5 184 0.08
93:6:1 75 50 1.5 193 0.08
93:6:1 75 50 1.5 178 0.06
93:6:1 100 66.7 1.5 154 0.1
93:6:1 100 100 1 176 0.09
Notes: Lipid concentration, OVA concentration, and ratio are based on theoretical 
values. *Size and PDI indicate experimental values.
Abbreviations: OVA, ovalbumin; SLIT, sublingual immunotherapy; PDI, polydispersity 
index; conc, concentration; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; 
DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; DOPE-PEG2000, 1,2-dioleoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; DOPE-
PEG1000, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-1000].
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fraction. OVA-POPC cationic liposomes had a concentra-
tion of 7.14 mg/mL OVA immediately after preparation. 
The protein that passed through the filter in a 1 day stored 
sample was 2.7% of the initial concentration (Figure 3). 
OVA concentration in the filtrate increased gradually, reduc-
ing the encapsulated OVA to a concentration of 5.2 mg/mL 
during the first 2 weeks after which the leakage seemed to 
be reduced significantly up to the end of the 2 months testing 
period. We speculate that there might be a certain amount 
of OVA that is associated with the liposome surface after 
SEC, which is the fraction that “leaks” (disassociates) from 
the liposomes over the first weeks. OVA-DOPC cationic 
liposomes with a start concentration of 6.76 mg/mL showed 
a comparable leakage/dissociation of OVA (7.8% of the 
encapsulated fraction after the first day). The encapsulated 
OVA concentration continued to decrease to 5.8 mg/mL 
after 2 weeks, after which no further leakage was observed 
(Figure 3). Again, we therefore speculate that the leakage 
Table 2 characterization of OVa-liposomes for in vivo experiments
Lipid 
composition
Short name Lipid conc 
(mM)
Diameter 
(nm)
PDI OVA encapsulation 
(mg/mL)
Lipid to 
protein ratio
POPC/DOTAP/DOPE-PEG1000
98:1:1 OVA-POPC neutral 80.9 148 0.088 7.52 10.8
93:6:1 OVA-POPC cationic 69.8 140 0.093 7.14 9.8
DOPC/DOTAP/DOPE-PEG1000
98:1:1 OVA-DOPC neutral 83.9 151 0.098 6.39 13.1
93:6:1 OVA-DOPC cationic 71.7 153 0.094 6.76 10.6
Abbreviations: OVA, ovalbumin; PDI, polydispersity index; conc, concentration; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-
phosphocholine; DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; DOPE-PEG1000, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000].
29$323&FDWLRQLF29$323&QHXWUDO³(PSW\´29$323&FDWLRQLF
29$323&FDWLRQLF29$323&QHXWUDO³(PSW\´29$323&FDWLRQLF
29$'23&FDWLRQLF29$'23&QHXWUDO³(PSW\´29$'23&FDWLRQLF
29$'23&FDWLRQLF29$'23&QHXWUDO³(PSW\´29$'23&FDWLRQLF










        
    



3R
O\GL
VSH
UVLW
\LQ
GH[



    
3RO
\GLV
SHU
VLW\
LQG
H[
'LD
PHW
HUV
L]H
QP

'LD
PHW
HUV
L]H
QP

0RQWKV 0RQWKV
0RQWKV0RQWKV
$
%
&
'
Figure 2 Physical stability and characterization of OVA-liposomes. 
Notes: Neutral or cationic formulated OVA-POPC or OVA-DOPC liposomes were tested over a period of 4.5 months using DLS where the liposomes were stored at 4°c. 
(A, C) Diameter of OVA-POPC and OVA-DOPC liposomes, respectively, measured as replicates 5× for 30 seconds each. (B, D) Polydispersity index for OVA-POPC and 
OVA-DOPC liposomes, respectively. Each time point represents mean ± SD of two distinct samples. 
Abbreviations: OVA, ovalbumin; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DLS, dynamic light scattering; 
SD, standard deviation.
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originates from outer membrane surface-associated OVA 
that is bound by electrostatic interaction between the cationic 
membrane and the negatively charged OVA. 
Prophylactic SLIT treatment of airway 
inflammation in mice
A mouse model of OVA-induced allergic airway inflam-
mation was used to evaluate if prophylactic SLIT with 
OVA-liposome formulations could reduce the induc-
tion of allergy-related inflammation to a higher extent 
than free OVA. To study the effect of SLIT with OVA-
liposomes as a function of surface charge and membrane 
fluidity, we encapsulated OVA in PEGylated neutral and 
cationic POPC and DOPC liposomes, respectively. As seen 
in Figure 4A, sublingual treatment with both neutral and 
cationic OVA-POPC and OVA-DOPC significantly reduced 
the percentage of eosinophils in BAL fluids compared to 
the sham-treated group. Moreover, SLIT treatment with 
neutral OVA-POPC and OVA-DOPC induced a significant 
reduction in the percentages of eosinophils compared to the 
SLIT-treated group with a corresponding dose of free OVA. 
A significant reduction was also observed following SLIT 
with cationic OVA-DOPC compared to SLIT with free 
OVA of the same dose. No differences with regard to BAL 
eosinophils between groups treated with OVA-POPC and 
OVA-DOPC, respectively, could be observed. SLIT with 
empty liposomes (containing no OVA only PBS) had no 
effect on reducing the development of airway inflammation 
(data not shown).
Allergen-specific IgE was significantly downregulated 
in mice receiving 2 weeks of SLIT with either neutral 
OVA-DOPC or cationic OVA-POPC formulations com-
pared to the sham-treated group, whereas SLIT with the 
corresponding dose of free OVA had no effect on the IgE 
levels (Figure 4B).
Proliferative responses of splenocytes from mice SLIT 
treated with OVA-liposomes were decreased two-fold, com-
pared to both the SLIT-treated group with the corresponding 
dose of free OVA and buffer SLIT-treated group (Figure 4C). 
Cytokine production was analyzed from the cell supernatant 
of splenocyte cultures after in vitro stimulation with OVA. 
Only four mice per group were used for cytokine evaluation 
which reduced the power of the analysis. Nonetheless, in 
comparison to sham-treated mice, reduced levels of IFN-γ 
were observed in supernatants of cells generated from mice 
SLIT treated with both neutral and cationic OVA-POPC 
and OVA-DOPC liposomes. Levels of IL-5 were downregu-
lated in mice treated with cationic OVA-DOPC liposomes. 
Cytokine levels in cell supernatants from mice SLIT treated 
with a corresponding dose of OVA compared to sham-treated 
mice did not differ. There was a tendency toward decreased 
levels of both IL-4 and IL-10 in mice SLIT treated with 
OVA-liposomes. No differences in the levels of IL-13 could 
be observed between the groups (Figure 5).
Discussion
IgE-mediated allergic diseases such as allergic asthma 
and rhinoconjunctivitis can be treated with either AIT or 
pharmacotherapy. Whereas pharmacotherapy only reduces 
symptoms, AIT offers the potential for a long-term disease-
modifying effect in addition to symptom relief.6 AIT has tra-
ditionally been administrated subcutaneously. However, the 
sublingual route of administration has gained increasing 
interest since it first appeared in the market in the beginning 
of the 1990s and was recognized as an alternative to SCIT in 
children and adults in 2001.30,31 The number and severity of 
systemic side effects for SLIT are much lower compared to 
SCIT and it has shown significant clinical efficacy compared 
to placebo.14,32,33 It has been demonstrated in many clinical 
studies34,35 and animal models of allergic diseases36,37 that the 
effect of SLIT, both clinical and immunological, depends on 
the individual allergen dose given with each administration. 
Concomitantly with an increased efficacy, the number and 
severity of adverse events also increase with dose. The target 
profile for an improved SLIT treatment is therefore improved 
safety with maintained or increased clinical efficacy, and 
increased patient convenience. We hypothesized that by using 
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Figure 3 OVA dissociation and leakage from liposomes.
Notes: OVA-liposomes were stored at 4°C and centrifuged at different time points 
using Amicon ultracel-100 membrane 100,000 MWCO filter units. The amount 
of OVA in the filtrate from both OVA-DOPC and OVA-POPC liposomes was 
quantified using amino acid analysis.
Abbreviations: OVA, ovalbumin; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine.
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liposomes as an allergen carrier, the amount of drug reaching 
the target site, at any given dose, could be increased compared 
to SLIT with a soluble-free allergen. Moreover, protection of 
the allergen inside a liposome may also prevent cross-linking 
between the allergen and existing allergen-specific IgE and 
hence contribute to reduced allergen-related side effects.
AIT requires immune cell processing of administered 
allergen to provide a treatment effect. For SLIT, it is not 
currently known if the primary effect of allergen processing 
occurs by APCs locally in the mucus or draining lymph 
nodes, or if the allergen diffuses to lymph nodes where it 
is captured and processed by APCs, but the former is the 
most prevalent hypothesis.8,9 Also, it is not well understood 
which APCs are involved in tolerance induction during 
SLIT. However, primarily DCs (myeloid and oral Langer-
hans cells) and macrophages have been described to play a 
role in antigen presentation after sublingual administration 
in humans.10,38 Likewise, DCs (plasmacytoid, myeloid, and 
oral Langerhans cells) and macrophage like cells have been 
suggested in mice.10,39 Immature DCs residing in mucosal 
tissue are highly efficient in probing the tissue environment 
and internalize nanocarriers such as liposomes by phagocy-
tosis or micropinocytosis.40,41 The internalization efficiency 
is dependent on particle size. In addition, previous reports 
$
29$

J





(
26
29$
323&
QHXW
29$
'23
&QHX
W
29$
323&
FDW
29$
'23
&FDW
29$
J %XIIH
U


  
 
  
%




29$
OJ(
QJ
P/
  


29$

J
29$
323&
QHXW
29$
'23
&QHX
W
29$
323&
FDW
29$
'23
&FDW
29$
J %XIIH
U
&







&RX
QWV
SHU
PLQ
XWH 

  
 

29$

J
29$
323&
QHXW
29$
'23
&QHX
W
29$
323&
FDW
29$
'23
&FDW
29$
J %XIIH
U
Figure 4 Effect of sublingual immunotherapy on immunological parameters.
Notes: Mice were treated sublingually with 10 µL of 50 µg OVA either as soluble-free protein or encapsulated in liposomes, 500 µg OVA as positive control for treatment, 
or PBS buffer. They were subsequently sensitized twice by intraperitoneal injections with 25 µg of alum-adsorbed OVA in 250 µL buffer solution followed by three intranasal 
challenges of 10 µg of OVA in 25 µL buffer solution. Mice were sacrificed the following day. (A) The percentages of eosinophils in bronchoalveolar lavage, (B) allergen-specific 
IgE in serum, and (C) proliferation of splenocytes following 6 days of in vitro stimulation with allergen were analyzed. Each dot represents an individual mouse and the error 
bars indicate mean + SEM, n=6–8. * indicates P,0.05, ** indicates P,0.01, *** indicates P,0.005, and **** indicates P,0.001.
Abbreviations: OVA, ovalbumin; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; neut, neutral; cat, cationic; 
EOS, eosinophils; SEM, standard error of means; PBS, phosphate-buffered saline.
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with intracutaneous application indicate that liposomes are 
capable of migrating from the administered site to the lymph 
nodes, depending on their size, where smaller liposomes 
(,200 nm) drain more efficiently to lymph nodes than 
larger particles.40,42
Allergic and acute inflammatory reactions are rarely 
seen in oral mucosa which maintains immune homeostasis 
by tolerating harmless commensals while at the same time 
recognizes and eliminates pathogens,10 which makes SLIT 
an attractive strategy as a site of administration of allergens 
during AIT. A general challenge with allergens used in SLIT 
is that they are rapidly cleared from the oral mucosa giving a 
short period of potential interactions with APCs. One possible 
approach to circumvent the rapid antigen clearance in the 
mucosa is to use liposomes as an allergen delivery system to 
modify clearance characteristics. PEG is a nontoxic polymer 
that is a gold standard in liposomology to control liposome 
interactions in biological environments, and PEG has been 
found to have bioadhesive properties toward mucus layers 
in tissues.23,43,44 Therefore, in order to protect the allergen 
from rapid clearance and to enhance its penetration through 
layers of the sublingual mucosa in an effective way, OVA 
was encapsulated into PEGylated phospholipid liposomes 
and the membrane surface charge was furthermore investi-
gated as an additional parameter to retain the allergen in the 
peripheral tissues and increase APC uptake after sublingual 
administration in mice.
POPC or DOPC lipids were used as the main lipid com-
ponents in the liposomes used in this study to encapsulate 
OVA delivery and we investigated the effect of liposome 
membrane fluidity/rigidity and surface charge for improving 
prophylactic SLIT in mice with OVA-liposomes in com-
parison with free OVA. The encapsulation of OVA in the 
investigated liposomes proved to be a challenge because of 
the high concentrations of lipid and OVA needed, which 
was primarily due to the electrostatic interaction between the 
negatively charged OVA and the positively charged liposome 
membrane that made extrusion and sonication challenging. 
It should be noted that this interaction also has a beneficial 
effect on OVA encapsulation efficiency. Introduction of PEG 
substantially reduced this challenge and it was possible to 
prepare liposomes in the desired size range (,200 nm) and 
with good stability. The formulated OVA-POPC and OVA-
DOPC liposomes were physically stable for .4 months 
Figure 5 Cytokine levels in supernatants from splenocyte cell cultures of mice treated sublingually with OVA-liposomes, free OVA solution, or PBS buffer. 
Notes: Single cell suspensions from spleens were in vitro stimulated during 5 days with 125 µg/mL OVA and cytokine levels were measured using a MULTI-SPOT® custom 
Cytokine Assays kit. Error bars indicate mean + SEM, n=4. * indicates P,0.05, ** indicates P,0.01.
Abbreviations: OVA, ovalbumin; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; neut, neutral; cat, cationic; 
SEM, standard error of means; PBS, phosphate-buffered saline.
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when preserved at 4°C, and the liposomes did not aggregate 
during this time.
The OVA-POPC and OVA-DOPC liposomes showed a 
statistically significant reduction of splenocyte proliferation 
and airway eosinophilia as well as nonsignificant downregu-
lations for OVA-specific IgE antibodies compared to corre-
sponding doses of free OVA. This indicates that prophylactic 
SLIT with OVA-POPC and OVA-DOPC liposomes prevents 
induction of allergic parameters when, SLIT is administered 
prior to allergic sensitization, more efficiently than SLIT 
treatment with free OVA. The enhanced effect may depend 
on the electrostatic interactions between cationic liposomes 
and negatively charged cell membranes, which in turn could 
improve the uptake and delivery of liposomes by DCs.45 
Analysis of cytokine production from the spleen revealed 
a significant downregulation for IFN-γ for all liposome for-
mulations compared to the sham-treated group. There was 
furthermore a tendency for lower levels of IL-5, IL-4, and 
IL-10 compared to sham-treated mice and free OVA for the 
cationic liposomes, although these were not significant. The 
free OVA data (positive control for treatment effect) are in 
line with previous data from our group and others,26 which 
has shown that SLIT with free OVA can prevent induction of 
Th2 responses such as airway eosinophilia, allergen-specific 
IgE, systemic T-cell proliferation, and Th2 cytokines, when 
SLIT is performed prior to allergic sensitization.4,46 The data 
in the present study indicate that liposomes are capable of 
improving the most important allergy-associated mechanisms 
such as cell proliferation and proinflammatory cytokine 
profiles, except for IL-13, which is an important cytokine in 
relation to airway inflammation and a major factor in Th2 
inflammation and tissue remodeling.
In the present study, the various liposomes tested gave 
comparable results and all were better than free OVA in 
inducing a tolerance effect. Future studies could include 
ultra-deformable liposomes where inspiration can be drawn 
from the pioneering work of Cevc et al for delivery of drugs 
across skin.21,47 Another parameter that might be considered 
in the future is to prepare smaller particles that could pen-
etrate easier through mucin fibers in the mucosa. Based on 
the general literature knowledge, cationic liposomes should 
result in a better efficacy due to electrostatic interactions with 
APC, if they translocate.45
Safety issues have not been specifically addressed in this 
study; however, lipids are generally biocompatible and a major 
constituent of cell membranes. Liposomes have been used in 
human clinical trials for allergen vaccination using subcu-
taneous injection where Dermatophagoides pteronyssinus 
extract encapsulated in DOPC/cholesterol liposomes has been 
shown to be well tolerated, safe, and efficacious.48 However, 
in the present study we did use a low molar ratio (1 mol% 
and 6 mol%) of cationic lipids (DOTAP) to formulate OVA. 
Cationic lipids have been found to induce in vivo toxicity 
when used in large amounts. However, we do not expect that 
the small amounts used in the present study will induce toxic-
ity. Even though we did not observe any adverse effects using 
the formulations in the present study, more detailed studies of 
toxicity should be carried out in future investigations.
In conclusion, the OVA-liposomes investigated in this 
project have a long shelf-life and both OVA-POPC and OVA-
DOPC liposomes used as drug delivery systems in this study 
enhanced the treatment efficacy when administered sublin-
gually compared to free OVA and consequently prohibit 
induction of allergic parameters when SLIT is performed 
prior to allergic sensitization.
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